SCHEMBL1362317

SCHEMBL1362317

CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)OC(=O)/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C)C(C)(C)CCC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.80
MAPT P10636 8/20 0.80
CYP3A4 P08684 7/20 0.80
RXRA P19793 5/20 0.80
RARA P10276 4/20 0.80
RARB P10826 4/20 0.80
RARG P13631 4/20 0.80
PTGS1 P23219 4/20 0.80
MAPK1 P28482 4/20 0.80
HIF1A Q16665 4/20 0.80
APP P05067 4/20 0.80
SNCA P37840 4/20 0.80
ALOX15 P16050 4/20 0.80
HSD17B10 Q99714 4/20 0.80
BLM P54132 3/20 0.80
LMNA P02545 3/20 0.80
MEN1 O00255 3/20 0.80
KMT2A Q03164 3/20 0.80
RXRB P28702 2/20 0.80
RXRG P48443 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862741 0.98 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
Alcohol SCHEMBL1362664 0.96 ALDH1A1 (0.73) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL7890783 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL7523937 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL11125160 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL5225545 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL21587 0.95 ALDH1A1 (0.77) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL27679011 0.94 ALDH1A1 (0.79) ALDH1A1MAPTCYP3A4RXRARARA
Glycolic Acid SCHEMBL6353225 0.94 ALDH1A1 (0.74) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL15609125 0.94 ALDH1A1 (0.78) ALDH1A1MAPTCYP3A4RXRARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744644-A1 COSMETIC PREPARATION FOR REJUVENATING THE SKIN Prima-Derm, S.L. (ES) 2026-05-20 EP claimed
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2026-02-19 US claimed
US-20250381129-A1 ANTI-AGING SKIN CARE COMPOSITION L'OREAL (FR) 2025-12-18 US claimed
WO-2025229086-A1 ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF SKINOSIVE (FR) 2025-11-06 WO claimed
EP-4622621-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL Symrise AG (DE) 2025-10-01 EP claimed
US-20250143988-A1 COMPOSTITION WITH STABILIZED TASTE AND ODOR SYMRISE AG (DE) 2025-05-08 US claimed
EP-3230302-B1 CARRIER MOLECULE COMPOSITIONS AND RELATED METHODS JYSK SKIN SOLUTIONS PTE LTD (SG) 2025-04-30 EP claimed
WO-2024136610-A1 COMPOSITION COMPRISING PH-SENSITIVE LIPID NANOPARTICLES CONTAINING CATIONIC MATERIAL 동아제약 주식회사 2024-06-27 WO claimed
US-12011498-B2 Compositions and methods for preventing and reversing aspects of aging CENTERS FOR AGE CONTROL INC (US) 2024-06-18 US claimed
WO-2024110023-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2024-05-30 WO claimed
EP-3230302-A1 CARRIER MOLECULE COMPOSITIONS AND RELATED METHODS Jjsk R & D Pte Ltd (SG) 2017-10-18 EP claimed
WO-2016092365-A1 CARRIER MOLECULE COMPOSITIONS AND RELATED METHODS JJSK R&D Pte Ltd (SG) 2016-06-16 WO claimed
US-20160166703-A1 Carrier Molecule Compositions and Related Methods JYSK SKIN SOLUTIONS PTE. LTD. (SG) 2016-06-16 US claimed
EP-2649986-A2 Cosmetic composition for rejuvenating the skin and corresponding method and uses Umbert Millet, Ignacio (ES) 2013-10-16 EP claimed
US-7173062-B2 Prevent skin wrinkling; using retinyl retinoate ENPRANI CO., LTD. (KR) 2007-02-06 US claimed
EP-1351919-A4 RETINOL DERIVATIVES AND PROCESS FOR PREPARING SAME ENPRANI CO LTD (KR) 2006-05-17 EP claimed
US-20040062781-A1 Retinol derivatives and process for preparing same ENPRANI CO., LTD. (KR) 2004-04-01 US claimed
EP-1351919-A1 RETINOL DERIVATIVES AND PROCESS FOR PREPARING SAME Enprani Co., Ltd. (KR) 2003-10-15 EP claimed
WO-2002057212-A1 RETINOL DERIVATIVES AND PROCESS FOR PREPARING SAME ENPRANI CO., LTD. (KR) 2002-07-25 WO claimed
US-6180670-B1 RETINYL ESTER AVON PRODUCTS, INC. 2001-01-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250143988-A1 COMPOSTITION WITH STABILIZED TASTE AND ODOR TAS2R16, TAS2R8, FFAR2 ALDH1A1 1076/4885MAPT 3109/4885CYP3A4 3246/4885
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL RBP4, LRAT, RARB ALDH1A1 156/4885MAPT 781/4885CYP3A4 2860/4885
US-20040062781-A1 Retinol derivatives and process for preparing same LRAT, RBP4, RBP1 ALDH1A1 181/4885MAPT 3561/4885CYP3A4 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.